Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases

详细信息    查看全文

• 作者：Antonio Martocchia ; Manuela Stefanelli…
• 关键词：Cortisol ; Metabolic syndrome ; Degenerative diseases ; Aging ; 11β ; Hydroxysteroid dehydrogenase type 1
• 刊名：Aging Clinical and Experimental Research
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：28
• 期：1
• 页码：17-23
• 全文大小：505 KB
• 参考文献：1.Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication 2:1–284
  2.Erkelens DW, de Bruin TWA, Cabezas MC (1993) Tulp syndrome. Lancet 342:1536–1537CrossRef PubMed
  3.Crepaldi G, Manzato E (1995) Polymetabolic syndrome. Minerva Endocrinol 20:155–160PubMed
  4.Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of aWHO consultation. Diabet Med 15:539–553CrossRef PubMed
  5.Balkau B, Charles MA (1999) Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16:442–443CrossRef PubMed
  6.Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
  7.Bloomgarden ZT (2003) American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care 26:1297–1303CrossRef PubMed
  8.Alberti KG, Zimmet P, Shaw J (2005) International Diabetes Federation (IDF) Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 366:1059–1062CrossRef PubMed
  9.Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752CrossRef PubMed
  10.Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRef PubMed
  11.Seth SM, Abd TT, Jones SR et al (2014) ACC/AHA Cholesterol treatment guideline. What was done well and what could be done better. J Am Coll Cardiol 63:2674–2678CrossRef
  12.Cornier MA, Dabelea D, Hernandez TL et al (2008) The metabolic syndrome. End Rev 29:777–822
  13.Maggi S, Noale M, Zambon A et al (2008) Validity of the ATP III diagnostic criteria for the metabolic syndrome in an elderly Italian Caucasian population: the Italian Longitudinal Study on Aging. Atherosclerosis 197:877–882CrossRef PubMed
  14.Stefanelli M, Martocchia A, De Marinis EA et al (2013) Prevalence of metabolic syndrome in cognitive impairment. Aging Clin Exp Res 25:351–352CrossRef PubMed
  15.Egger G, Dixon J (2010) Obesity prevention. Inflammatory effects of nutritional stimuli: further support for the need for a big picture approach to tackling obesity and chronic disease. Obes Rev 11:137–149CrossRef PubMed
  16.Fehevari Z (2012) Focus on the inflammasome. An inflammatory assemblage. Nat Immunol 13:320CrossRef
  17.Després JP, Lemieux I, Bergeron J et al (2008) Cardiometabolic risk abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 28:1039–1049CrossRef PubMed
  18.Bjorntorp P (1991) Visceral fat accumulation: the missing link between psychosocial factors and cardiovascular disease? J Intern Med 230:195–201CrossRef PubMed
  19.Björntorp P (2001) Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2:73–86CrossRef PubMed
  20.Martocchia A, Curto M, Toussan L et al (2011) Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Rec Patents CNS Drug Discov 6:196–204CrossRef
  21.Falaschi P, Martocchia A, Proietti A et al (1994) Immune system and the hypothalamus pituitary–adrenal axis. Common words for a single language. Ann N Y Acad Sci 29:89–111
  22.McEwen BS, Gianaros PJ (2010) Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci 1186:190–222PubMedCentral CrossRef PubMed
  23.Charmandari E, Tsigos C, Chrousos G (2005) Endocrinology of the stress response. Annu Rev Physiol 67:259–284CrossRef PubMed
  24.Herman JP, Ostrander MM, Mueller NK et al (2005) Limbic system mechanisms of stress regulation: hypothalamo-pituitary adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry 29:1201–1213CrossRef PubMed
  25.Peiffer A, Barden N, Meaney MJ (1991) Age-related changes in glucocorticoid receptor binding and mRNA levels in the rat brain and pituitary. Neurobiol Aging 12:475–479CrossRef PubMed
  26.Sapolsky RM, Krey LC, McEwen BS (1983) The adrenocortical stress-response in the aged male rat: impairment of recovery from stress. Exp Gerontol 18:55–64CrossRef PubMed
  27.Van Cauter E, Leproult R, Kupfer DJ (1996) Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocr Metab 81:2468–2473PubMed
  28.Falaschi P (1993) Neuroendocrinoimmunology. 94° Congr SIMI Ed Luigi Pozzi, Rome, pp 315–416
  29.Tomlinson JW, Stewart PM (2004) “Cushing’s disease of the omentum”—fact or fiction? J Endocrinol Invest 27:171–174CrossRef PubMed
  30.Duclos M, Marquez Pereira P, Barat P et al (2005) Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res 13:1157–1166CrossRef PubMed
  31.Seeman TE, McEwen BS, Rowe JW et al (2001) Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proc Natl Acad Sci 98:4770–4775PubMedCentral CrossRef PubMed
  32.Meco G, Formisano R, Falaschi P et al (1985) Dexamethasone non-suppressor Parkinsonian patients: a subgroup with depression and mental impairment. In: Burrows GD, Norman TR, Dennerstein L (eds) Clinical and pharmacological studies in psychiatric disorders. John Lippey, London, pp 171–185
  33.Dekker MJ, Koper JW, Van Aken MO et al (2008) Salivary cortisol is related to atherosclerosis of carotid arteries. J Clin Endocrinol Metab 93:3741–3747CrossRef PubMed
  34.Chiodini I (2011) Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96:1223–1236CrossRef PubMed
  35.Wirtz PH, Von Känel R, Emini L et al (2007) Evidence for altered hypothalamus–pituitary–adrenal axis functioning in systemic hypertension: blunted cortisol response to awakening and lower negative feedback sensitivity. Psychoneuroendocrinology 32:430–436CrossRef PubMed
  36.Gruenewald TL, Seeman TE, Karlamangla AS et al (2009) Allostatic load and frailty in older adults. J Am Geriatr Soc 57:1525–1531PubMedCentral CrossRef PubMed
  37.Solfrizzi V, Scafato E, Frisardi V et al (2012) Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. Age (Dordr) 34:507–517CrossRef
  38.Waters DL, Qualls CR, Dorin RI et al (2008) Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol A Biol Sci 63:536–541CrossRef
  39.Scafato E, Gandin C, Galluzzo L et al (2010) Prevalence of aging-associated cognitive decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer’s disease (IPREA). Aging Clin Exp Res 22:440–449CrossRef PubMed
  40.Huang CW, Lui CC, Chang WN et al (2009) Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease. J Clin Neurosci 16:1283–1286CrossRef PubMed
  41.Raffaitin C, Tzourio C, Gin E et al (2009) Metabolic syndrome and risk for incident Alzheimer disease or vascular dementia: the three-city study. Diabetes Care 32:169–174PubMedCentral CrossRef PubMed
  42.Vanhanen M, Koivisto K, Moilanen L et al (2006) Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67:843–847CrossRef PubMed
  43.Stefanelli M, Martocchia A, De Marinis EA et al (2014) Treatment of insulin resistance in the neurodegeneration. Recent Patents CNS Drug Discovery 9:54–63CrossRef PubMed
  44.Murakami H, Nigawara T, Sakihara S et al (2010) The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing’s disease. Endocr J 57:267–272CrossRef PubMed
  45.Hamer M, O’Donnell K, Lahiri A et al (2010) Salivary cortisol responses to mental stress are associated with coronary artery calcification in healthy men and women. Eur Heart J 31:424–429CrossRef PubMed
  46.Dennison E, Hindmarsh P, Fall C et al (1999) Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 84:3058–3063PubMed
  47.Maggi S, Siviero P, Gonnelli S et al (2011) The burden of previous fractures in hip fracture patients. The Break Study. Aging Clin Exp Res 23:183–186CrossRef PubMed
  48.Zillikens MC, Uitterlinden AG, Van Leeuwen JP et al (2010) The role of body mass index, insulin, and adiponectin in the relation between fat distribution and bone mineral density. Calcif Tissue Int 86:116–125PubMedCentral CrossRef PubMed
  49.Doherty TM, Asotra K, Fitzpatrick LA et al (2003) Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 100:11201–11206PubMedCentral CrossRef PubMed
  50.Helas S, Goettsch C, Schoppet M et al (2009) Inhibition of receptor activator of NF-kappa B ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175:473–478PubMedCentral CrossRef PubMed
  51.Martocchia A, Toussan L, Stefanelli M et al (2011) Association of severity of osteoarthritis and carotid atherosclerosis in patients with metabolic syndrome. Rheumatol Open Access J 1:1–3
  52.Stewart PM, Krozowski ZS (1999) 11β-Hydroxysteroid dehydrogenase. Vitam Horm 57:249–324CrossRef PubMed
  53.Basu R, Singh RJ, Basu A et al (2004) Splanchnic cortisol production occurs in humans evidence for conversion of cortisone to cortisol via the 11-β hydroxysteroid dehydrogenase (11β-HSD) type 1 pathway. Diabetes 53:2051–2059CrossRef PubMed
  54.Moisan MP, Seckl JR, Edwards CR (1990) 11β-Hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. Endocrinology 127:1450–1455CrossRef PubMed
  55.Veilleux A, Rhéaume C, Daris M et al (2009) Omental adipose tissue type 1 11beta-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women. J Clin Endocrinol Metab 94:3550–3557CrossRef PubMed
  56.Wake DJ, Rask E, Livingstone DE et al (2003) Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983–3988CrossRef PubMed
  57.Cooper MS, Rabbitt EH, Goddard PE et al (2002) Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979–986CrossRef PubMed
  58.Morton NM, Paterson JM, Masuzaki H et al (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931–938CrossRef PubMed
  59.Martocchia A, Stefanelli M, Falaschi GM et al (2013) Targets of anti-glucocorticoid therapy for stress-related disease. Recent Patents CNS Drug Discov 8:79–87CrossRef
  60.Alberts P, Engblom L, Edling N et al (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528–1532CrossRef PubMed
  61.Hermanowski-Vosatka A, Balkovec JM, Cheng K et al (2005) 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517–527PubMedCentral CrossRef PubMed
  62.Rosenstock J, Bananer S, Fonseca VA et al (2010) The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled Bb metformin monotherapy. Diabetes Care 33:1516–1522PubMedCentral CrossRef PubMed
  63.Feig PU, Shah S, Hermanowski-Vosatka A et al (2011) Effects of an 11-betahydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 13:498–504CrossRef PubMed
  64.Shah S, Hermanowski-Vosatka A, Gibson K et al (2011) Efficacy and safety of the selective 11β-HSD1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J Am Soc Hypertension 5:166–176CrossRef
  
• 作者单位：Antonio Martocchia (1)
  Manuela Stefanelli (1)
  Giulia Maria Falaschi (2)
  Lavinia Toussan (1)
  Claudio Ferri (2)
  Paolo Falaschi (1)
  
  1. Geriatric Unit, Faculty of Medicine and Psychology, Sapienza University of Rome, S. Andrea Hospital, Via di Grottarossa 1035, 00199, Rome, Italy
  2. Department of Life, Health and Environmental Sciences, University of L’Aquila, Viale S. Salvatore, Delta 6 Building, Coppito, 67100, L’Aquila, Italy
  
• 刊物主题：Geriatrics/Gerontology;
• 出版者：Springer International Publishing
• ISSN：1720-8319

文摘

The metabolic syndrome (MetS) presents an increasing prevalence in elderly people. A significant role in MetS is played by the stress response and cortisol. The hypothalamic–pituitary–adrenal (HPA) axis activity is increased by central (loss of hippocampal glucocorticoid receptors) and peripheral (11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1, hyperactivity) mechanisms. The HPA hyperactivity has been found in chronic diseases affecting the endocrine (abdominal obesity with MetS, type 2 diabetes), cardiovascular (atherosclerosis, essential hypertension), and nervous systems (dementia, depression), in aging. A novel therapeutic approach (11β-HSD1 inhibition) is promising in treating the HPA axis hyperactivity in chronic diseases with MetS. A large-scale national clinical trial (AGICO, AGIng, and COrtisol study) has been proposed by our group to evaluate the role of cortisol and MetS in the main pathologies of aging (vascular and degenerative dementia, cardiovascular diseases, type 2 diabetes, abdominal obesity). Keywords Cortisol Metabolic syndrome Degenerative diseases Aging 11β-Hydroxysteroid dehydrogenase type 1